Medical Device JCAs Launch and NICE Methodology Shifts

Episode 18 — 01 June 2026 Medical device JCAs begin this month as NICE refines implementation guidance and biosimilar value assessment approaches. The hosts disagree on whether NICE's procedural simplifications strengthen or weaken evidence standards. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast  GS1M3fTk8J53NF2ecagc

Transcript

SPEAKER_00 0:00

Welcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus with Sarah. Today, medical device, JCA's starting June, NICE's updated tranxamic acid guidance, and the Natalismab Biosimilar Decision Logic. Let's get into it.

SPEAKER_01 0:17

The EU JCA medical device rollout begins this month with approximately five assessments for high-risk devices. Class 22B3 and Class D in vitro diagnostics are entering formal JCA process according to the HTCG annual work program.

SPEAKER_00 0:32

This is the real test case for JCA methodology beyond pharmaceuticals. Medical devices present fundamentally different evidence challenges, shorter clinical trial programs, iterative development cycles, learning curve effects that don't exist in drug assessment.

SPEAKER_01 0:49

Exactly. And with only five assessments launching, they're clearly being cautious about capacity. The question is whether the methodology framework developed for pharmaceuticals can handle the evidence. Heterogeneity we see in device dossiers.

SPEAKER_00 1:02

The learning curve issue alone could break their current approach. Device performance improves with surgical experience in ways that pharmaceutical efficacy simply doesn't. You can't model that with traditional clinical endpoints.

SPEAKER_01 1:15

I plus the commercial implications are immediate. Unlike drugs where you might have 12, 18-month HDA timelines, device companies need faster market access to generate the real-world evidence that actually matters for long-term adoption.

SPEAKER_00 1:29

Nice updated their tranhexamic acid guidelines on May 13th, removing the requirement for clinicians to estimate blood loss during surgery. They're calling it procedural simplification, focusing just on bleeding risk rather than quantified loss estimates.

SPEAKER_01 1:45

This looks like NICE trying to improve implementation compliance by reducing administrative burden. But I'm skeptical about whether removing the blood loss estimation actually maintains the same evidence standard.

SPEAKER_00 1:56

The clinical effectiveness doesn't change based on administrative complexity. If anything, the blood loss estimation requirement was creating artificial precision where none existed. Most surgical blood loss estimates are notoriously inaccurate anyway.

SPEAKER_01 2:11

But that's exactly my point. If the blood loss estimates were unreliable, then the original evidence base that supported the recommendation might have been built on weak implementation assumptions. Simplifying the guidance doesn't fix the underlying evidence gap.

SPEAKER_00 2:25

You're conflating research evidence with clinical implementation guidance. The RCT evidence for TXA effectiveness is robust, regardless of how individual clinicians estimate blood loss in practice. NICE is just acknowledging implementation reality.

SPEAKER_01 2:40

I disagree. When you change the implementation criteria, you're potentially changing the patient population that receives treatment. That has direct implications for real-world effectiveness and cost effectiveness that weren't captured in the original economic model.

SPEAKER_00 2:54

The Natalizu Mab decision demonstrates NICE's increasingly sophisticated biosimilar assessment approach. They recommended subcutaneous tisobri and teruco biosimilar infusion for highly active relapsing remitting MS, but explicitly excluded intravenous tissubri on cost-effectiveness grounds.

SPEAKER_01 3:13

This is smart positioning for pregnancy planning patients since Natala Zumab can be used during pregnancy, unlike other highly effective DMTs. But the formulation-specific cost-effectiveness analysis shows how complex biosimilar value assessment is becoming.

SPEAKER_00 3:27

What's interesting is the differentiation within the same molecule based purely on delivery mechanism and cost structure. They're essentially saying the clinical benefit is equivalent, but the economic value proposition differs by formulation.

SPEAKER_01 3:41

It also signals to manufacturers that biosimilar strategies need formulation-specific economic modeling, not just bioequivalence demonstrations. The commercial implications extend beyond simple price competition to value-based differentiation.

SPEAKER_00 3:55

The EMA welcomed the Critical Medicines Act political agreement on May 12th, highlighting improved availability and production of critical medicines across the EU. Their executive steering group will conduct supply chain vulnerability assessments to inform policy measures.

SPEAKER_01 4:10

This connects directly to HTA methodology because supply chain resilience becomes part of the value equation. When you're assessing critical medicines, availability risk should factor into health technology assessment frameworks.

SPEAKER_00 4:22

The supply chain vulnerability assessments could generate valuable real-world data on medicine shortages and alternative therapy utilization patterns. That data becomes input for future HTA economic modeling.

SPEAKER_01 4:34

But it also creates regulatory complexity. If EMA identifies supply chain vulnerabilities for specific medicines, HTA bodies might need to adjust their cost-effectiveness thresholds or recommendation frameworks to account for availability risk.

SPEAKER_00 4:48

Medical devices hit JCA methodology this month. NICE continues refining implementation guidance while developing more sophisticated value differentiation approaches.

SPEAKER_01 4:57

The question is whether these procedural simplifications actually strengthen evidence standards or just make weak implementation more palatable. We'll see how device JCAs handle the methodology gaps.

SPEAKER_00 5:09

Back tomorrow on AccessBrief, show notes at outcomes analytica.no.